RxDoctor Payments DataLook up a doctor →

Rajiv Tayal

Interventional Cardiology · Fredericksburg, VANPI 1134457898

Payments from drug & device makers

$1,968,145in general payments, 2019–2025

Across 1,446 payments — averaging $1361.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cathworks, Inc.$555K
  • Abiomed$555K
  • Edwards Lifesciences$468K
  • Medtronic$244K
  • Shockwave Medical, Inc$89K
  • Boston Scientific$21K
  • plus $35K from 38 others
$342in research payments, 2019–2025

Across 1 payment — averaging $341.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$342

What the payments were for

  • Consulting fees$172,47518%
  • Speaking & faculty fees$564,64457%
  • Travel & lodging$204,79421%
  • Food & beverage$41,5444%
  • Education$170%
  • Entertainment$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,968,145 in reported general payments places this provider in the 95th percentile of 176 interventional cardiology providers in Virginia.

See all interventional cardiology providers in Virginia

Medicare billing

Part B allowed, 2024
$337,244
Medicare patients
483
Services billed
2,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$61,879
BrilintaTicagrelor25$30,374
EntrestoSacubitril/Valsartan15$17,908
Praluent PenAlirocumab18$15,961
Repatha SureclickEvolocumab17$13,589
Metoprolol Succinate120$1,663
ClopidogrelClopidogrel Bisulfate96$1,337
Rosuvastatin Calcium66$1,169
Atorvastatin Calcium103$925
Amlodipine Besylate45$501
Ezetimibe11$498
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$417
Carvedilol25$347
Potassium Chloride19$341
Losartan Potassium32$294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$29$61,87951 claims
AstraZenecaBrilinta$106$30,37425 claims
NovartisEntresto$324$17,90815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 176 interventional cardiology providers in Virginia.

Other interventional cardiology in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →